HUE033561T2 - Expresszió vektor - Google Patents
Expresszió vektor Download PDFInfo
- Publication number
- HUE033561T2 HUE033561T2 HUE09733074A HUE09733074A HUE033561T2 HU E033561 T2 HUE033561 T2 HU E033561T2 HU E09733074 A HUE09733074 A HU E09733074A HU E09733074 A HUE09733074 A HU E09733074A HU E033561 T2 HUE033561 T2 HU E033561T2
- Authority
- HU
- Hungary
- Prior art keywords
- microliter
- plasmid
- dna
- pcr
- bifidobacterium
- Prior art date
Links
- 239000013604 expression vector Substances 0.000 title description 30
- 239000013612 plasmid Substances 0.000 claims description 194
- 239000013598 vector Substances 0.000 claims description 17
- 206010003549 asthenia Diseases 0.000 claims 1
- 235000012976 tarts Nutrition 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 135
- 108090000623 proteins and genes Proteins 0.000 description 110
- 241000588724 Escherichia coli Species 0.000 description 83
- 239000011543 agarose gel Substances 0.000 description 74
- 241001608472 Bifidobacterium longum Species 0.000 description 72
- 102000004169 proteins and genes Human genes 0.000 description 68
- 241000894006 Bacteria Species 0.000 description 65
- 239000012634 fragment Substances 0.000 description 55
- 239000000047 product Substances 0.000 description 55
- 239000002773 nucleotide Substances 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 52
- 230000000259 anti-tumor effect Effects 0.000 description 50
- 239000000872 buffer Substances 0.000 description 48
- 238000000034 method Methods 0.000 description 48
- 125000003729 nucleotide group Chemical group 0.000 description 48
- 238000000746 purification Methods 0.000 description 45
- 244000005700 microbiome Species 0.000 description 44
- 239000000126 substance Substances 0.000 description 41
- 241000186000 Bifidobacterium Species 0.000 description 40
- 102000000311 Cytosine Deaminase Human genes 0.000 description 36
- 108010080611 Cytosine Deaminase Proteins 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 34
- 229940009291 bifidobacterium longum Drugs 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 230000009466 transformation Effects 0.000 description 34
- 239000000499 gel Substances 0.000 description 30
- 230000010076 replication Effects 0.000 description 29
- 102000004190 Enzymes Human genes 0.000 description 28
- 108090000790 Enzymes Proteins 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- 238000001962 electrophoresis Methods 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 27
- 238000010367 cloning Methods 0.000 description 26
- 239000003550 marker Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 108091008146 restriction endonucleases Proteins 0.000 description 23
- 238000003776 cleavage reaction Methods 0.000 description 21
- 230000007017 scission Effects 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 238000012258 culturing Methods 0.000 description 19
- 238000010828 elution Methods 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 18
- 239000003636 conditioned culture medium Substances 0.000 description 18
- 229910002092 carbon dioxide Inorganic materials 0.000 description 17
- 239000012531 culture fluid Substances 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 17
- 239000001569 carbon dioxide Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 229960004413 flucytosine Drugs 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 15
- 238000012790 confirmation Methods 0.000 description 13
- 230000003635 deoxygenating effect Effects 0.000 description 13
- 238000006911 enzymatic reaction Methods 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 241000186012 Bifidobacterium breve Species 0.000 description 11
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 11
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 11
- 229960002949 fluorouracil Drugs 0.000 description 11
- 238000005194 fractionation Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000013600 plasmid vector Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000193403 Clostridium Species 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 102000012410 DNA Ligases Human genes 0.000 description 9
- 108010061982 DNA Ligases Proteins 0.000 description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 238000000246 agarose gel electrophoresis Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229940004120 bifidobacterium infantis Drugs 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 101100476566 Campylobacter jejuni aad9 gene Proteins 0.000 description 8
- 101100476567 Enterococcus faecalis spc gene Proteins 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 241000194033 Enterococcus Species 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960000268 spectinomycin Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 description 5
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 5
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 101710096438 DNA-binding protein Proteins 0.000 description 4
- 108010023191 Streptomycin 3''-adenylyltransferase Proteins 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229960000511 lactulose Drugs 0.000 description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 3
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 3
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010060309 Glucuronidase Proteins 0.000 description 3
- 102000053187 Glucuronidase Human genes 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 3
- 102000004459 Nitroreductase Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008051 TBE buffer Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 208000023589 ischemic disease Diseases 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 238000013411 master cell bank Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020001162 nitroreductase Proteins 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 101150107738 repB gene Proteins 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241001134770 Bifidobacterium animalis Species 0.000 description 2
- 101150028326 CD gene Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101100382321 Caenorhabditis elegans cal-1 gene Proteins 0.000 description 1
- 101100127892 Caenorhabditis elegans let-60 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000004182 Congenital stromal corneal dystrophy Diseases 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108050008922 Histone-like DNA-binding proteins Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 208000019493 atypical carcinoid tumor Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- WOCXQMCIOTUMJV-UHFFFAOYSA-N cb1954 Chemical compound C1=C([N+]([O-])=O)C(C(=O)N)=CC(N2CC2)=C1[N+]([O-])=O WOCXQMCIOTUMJV-UHFFFAOYSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 108010060371 endo-N-acetylmuramidase Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12452808P | 2008-04-17 | 2008-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE033561T2 true HUE033561T2 (hu) | 2017-12-28 |
Family
ID=40792658
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE09733074A HUE033561T2 (hu) | 2008-04-17 | 2009-04-16 | Expresszió vektor |
| HUE09733604A HUE039768T2 (hu) | 2008-04-17 | 2009-04-17 | Terápiás szer anaerob betegségekre |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE09733604A HUE039768T2 (hu) | 2008-04-17 | 2009-04-17 | Terápiás szer anaerob betegségekre |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8383398B2 (enExample) |
| EP (2) | EP2274422B1 (enExample) |
| JP (3) | JP5735804B2 (enExample) |
| KR (3) | KR101674977B1 (enExample) |
| CN (2) | CN102046791B (enExample) |
| CA (2) | CA2721653C (enExample) |
| DK (2) | DK2274422T3 (enExample) |
| ES (2) | ES2628378T3 (enExample) |
| HU (2) | HUE033561T2 (enExample) |
| PL (2) | PL2274422T3 (enExample) |
| PT (2) | PT2274422T (enExample) |
| WO (2) | WO2009128272A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8535939B2 (en) | 2010-01-29 | 2013-09-17 | Anaeropharma Science, Inc. | Transfection vector |
| US20130095072A1 (en) * | 2010-01-29 | 2013-04-18 | Anaeropharma Science, Inc. | Therapeutic agent for ischemic diseases |
| EP2274422B1 (en) * | 2008-04-17 | 2017-03-15 | Anaeropharma Science, Inc. | Expression vector |
| US9730968B2 (en) | 2008-04-17 | 2017-08-15 | Anaeropharma Science, Inc. | Therapeutic agent for ischemic diseases |
| US8338162B2 (en) * | 2009-04-17 | 2012-12-25 | Anaeropharma Science, Inc. | Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium |
| WO2013008881A1 (ja) * | 2011-07-13 | 2013-01-17 | 株式会社アネロファーマ・サイエンス | 虚血性疾患治療薬 |
| KR20170088866A (ko) | 2014-12-03 | 2017-08-02 | 가부시키가이샤 아네로파마·사이엔스 | 공발현 플라스미드 |
| KR101892722B1 (ko) * | 2015-01-19 | 2018-08-28 | 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 | 허혈성 질환 치료제 |
| LU100900B1 (de) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen |
| WO2021038975A1 (ja) | 2019-08-28 | 2021-03-04 | 株式会社アネロファーマ・サイエンス | ダイアボディ型ＢｓＡｂを発現・分泌するビフィドバクテリウム属細菌 |
| CN112999215B (zh) * | 2019-12-20 | 2024-06-21 | 复旦大学 | 呋喃酮糖苷类化合物的应用 |
| CN115400154A (zh) * | 2022-08-10 | 2022-11-29 | 深圳未知君生物科技有限公司 | 长双歧杆菌在制备治疗自闭症谱系障碍的药物中的应用 |
| WO2024187069A1 (en) * | 2023-03-08 | 2024-09-12 | University Of Florida Research Foundation, Incorporated | Engineering enterobacteria to site-specifically activate the anticancer prodrug 5-fluorocytosine for treating colon cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8713601D0 (en) * | 1987-06-10 | 1987-07-15 | Unilever Plc | Fermentation |
| WO1991009131A1 (en) * | 1989-12-20 | 1991-06-27 | Valio Finnish Cooperative Dairies Association | Cloning vector for use in lactic acid bacteria |
| US6984513B2 (en) | 1994-03-03 | 2006-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
| US6416754B1 (en) | 1994-03-03 | 2002-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
| TW357191B (en) * | 1996-06-04 | 1999-05-01 | Food Industry Development Res Institute | Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method |
| JP2000060541A (ja) * | 1998-08-27 | 2000-02-29 | Fuyuki Mitsuyama | ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤 |
| JP3642755B2 (ja) | 2000-09-21 | 2005-04-27 | 純 天野 | 嫌気性菌を用いた遺伝子治療用医薬 |
| CA2342040C (en) * | 2000-09-21 | 2012-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anaerobic bacterium as a drug for cancer gene therapy |
| US7008633B2 (en) * | 2000-12-18 | 2006-03-07 | Board Of Regents, The University Of Texas System | Local regional chemotherapy and radiotherapy using in situ hydrogel |
| KR100457879B1 (ko) * | 2001-02-24 | 2004-11-18 | 주식회사 비피도 | 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법 |
| PT2088193E (pt) | 2004-11-24 | 2011-02-24 | Anaeropharma Science Inc | Novo vector vaivém |
| ES2548516T3 (es) * | 2005-01-21 | 2015-10-19 | The Research Foundation Of The State University Of New York | Métodos para el tratamiento de la capsulitis adhesiva |
| EP1867714B1 (en) | 2005-04-08 | 2013-09-18 | Anaeropharma Science Inc. | 5-fluorouracil-resistant bacteria and method for production thereof |
| CA2646244A1 (en) * | 2006-03-27 | 2007-10-04 | Government Of The United States Of Americas, As Represented By The Secre | Tetracycline compounds and methods of treatment |
| GB2439310A (en) * | 2006-04-13 | 2007-12-27 | Ambrozea Inc | Fermentation residuals from genetically-modified microorganisms |
| JP5048661B2 (ja) | 2006-05-24 | 2012-10-17 | 株式会社アネロファーマ・サイエンス | 遺伝子輸送担体作製方法 |
| EP2274422B1 (en) * | 2008-04-17 | 2017-03-15 | Anaeropharma Science, Inc. | Expression vector |
-
2009
- 2009-04-16 EP EP09733074.0A patent/EP2274422B1/en active Active
- 2009-04-16 CA CA2721653A patent/CA2721653C/en active Active
- 2009-04-16 JP JP2010541633A patent/JP5735804B2/ja active Active
- 2009-04-16 KR KR1020107025821A patent/KR101674977B1/ko not_active Expired - Fee Related
- 2009-04-16 WO PCT/JP2009/001768 patent/WO2009128272A1/en not_active Ceased
- 2009-04-16 PT PT97330740T patent/PT2274422T/pt unknown
- 2009-04-16 ES ES09733074.0T patent/ES2628378T3/es active Active
- 2009-04-16 DK DK09733074.0T patent/DK2274422T3/en active
- 2009-04-16 CN CN2009801205839A patent/CN102046791B/zh active Active
- 2009-04-16 PL PL09733074T patent/PL2274422T3/pl unknown
- 2009-04-16 HU HUE09733074A patent/HUE033561T2/hu unknown
- 2009-04-16 US US12/425,001 patent/US8383398B2/en not_active Expired - Fee Related
- 2009-04-17 WO PCT/JP2009/001776 patent/WO2009128275A1/en not_active Ceased
- 2009-04-17 KR KR1020107025820A patent/KR101671283B1/ko not_active Expired - Fee Related
- 2009-04-17 EP EP09733604.4A patent/EP2280717B1/en active Active
- 2009-04-17 PT PT09733604T patent/PT2280717T/pt unknown
- 2009-04-17 CA CA2721664A patent/CA2721664C/en active Active
- 2009-04-17 US US12/988,181 patent/US8470311B2/en active Active
- 2009-04-17 DK DK09733604.4T patent/DK2280717T3/en active
- 2009-04-17 KR KR1020167022911A patent/KR20160102584A/ko not_active Ceased
- 2009-04-17 ES ES09733604.4T patent/ES2686080T3/es active Active
- 2009-04-17 CN CN2009801205843A patent/CN102046190B/zh active Active
- 2009-04-17 JP JP2010541634A patent/JP5514735B2/ja active Active
- 2009-04-17 PL PL09733604T patent/PL2280717T3/pl unknown
- 2009-04-17 HU HUE09733604A patent/HUE039768T2/hu unknown
-
2013
- 2013-01-24 US US13/749,428 patent/US20130122582A1/en not_active Abandoned
-
2014
- 2014-12-09 JP JP2014248772A patent/JP6089025B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2274422T3 (en) | expression | |
| KR102853088B1 (ko) | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 | |
| CN110551713B (zh) | 用于修饰梭状芽孢杆菌属细菌的优化的遗传工具 | |
| KR101850162B1 (ko) | 형질전환용 플라스미드 | |
| CN111492056B (zh) | 用于细胞的遗传修饰的非整合型dna载体 | |
| AU2016308591B2 (en) | Delivery vehicle | |
| KR20220015499A (ko) | 리소좀 장애를 위한 유전자 요법 | |
| TW202235615A (zh) | 工程化之t細胞 | |
| US20090263873A1 (en) | Linear vectors, host cells and cloning methods | |
| AU2017252409A1 (en) | Compositions and methods for nucleic acid expression and protein secretion in bacteroides | |
| CN113614229B (zh) | 遗传修饰的梭菌属细菌、其制备和用途 | |
| AU2023265204A1 (en) | Virus-derived construct plasmid library and construction of same | |
| CN114286857B (zh) | 用于修饰细菌的优化的遗传工具 | |
| KR20080030956A (ko) | 개선된 조절 발현 체계를 사용한 질병의 치료 | |
| KR20210109537A (ko) | 아시네토박터 바우마니의 검출을 위한 비-복제 형질 도입 입자 및 형질 도입 입자 기반의 리포터 시스템 | |
| CN115404193A (zh) | 重组微生物及其用于生产1,5-戊二胺的方法 | |
| HK40048832B (zh) | 用於溶酶体障碍的基因疗法 | |
| HK1122837A (en) | Treatment of disease using an improved regulated expression system |